Filters
Pregnant women with nonalcoholic fatty liver disease (NAFLD) face a greater risk of adverse pregnancy events, suggests a genome-wide association study.
Gestational hypertension, preeclampsia, and eclampsia were associated with an increased risk of new-onset migraine, headache, epilepsy, sleep disorder, or mental fatigue within months to years after giving birth, a Swedish study found.
The use of the antiandrogen enzalutamide in patients with granulosa cell ovarian tumour (GCT) falls short in terms of significant radiological response or clinical benefit, according to a phase II trial.
Enlonstobart, a fully humanized and high-affinity anti-PD-1 immunoglobulin G4 monoclonal antibody, shows therapeutic potential in patients with PD-L1 positive recurrent or metastatic cervical cancer (r/mCC), while having an acceptable safety profile, according to an open-label phase II study.
In the treatment of women with early pregnancy loss, adding mifepristone to misoprostol helps reduce the incidence of treatment failure as compared with misoprostol alone, according to a retrospective study.
Administering hyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreductive surgery for recurrent ovarian cancer helps prolong overall survival, according to the results of the phase III open-label CHIPOR trial.
Breast cancer patients undergoing adjuvant endocrine therapy appear to experience symptoms similar in type and intensity to those of symptomatic menopausal women, according to a retrospective study. However, the use of aromatase inhibitors is associated with less severe depressive symptoms.
First-time mothers who sustain life-threatening events during pregnancy, delivery, and up to 42 days postpartum are less likely to have more children, as suggested in a large retrospective study.
A study presented at RCOG 2024 supports the non-removal of incidentally identified cervical polyps, given the low incidence of malignancy and the cost-effectiveness of such approach.
Tranexamic acid was as effective as norethisterone in reducing menstrual blood loss and the duration of menstrual period in women with heavy menstrual bleeding (HMB), according to a study presented at RCOG 2024.
